TIS 0.00% 0.0¢ tissue therapies limited

update, page-3

  1. 472 Posts.
    lightbulb Created with Sketch. 12
    What comes out of the February meeting "should" be a very good guide for the timelines to CE Mark approval. We can use past referrals to EMA as guidance and we know that this is the last phase of referral so whereas in the past there has always been another possible regulatory referral, that's not the case now. EMA is it. Of course there is always potential for them to say no or find some fault which needs to be fixed and that may prolong the process but frankly I'd be surprised if it didn't all run accoring to their timelines from this point.

    GLTA and let's see what the next month brings.

    Rev
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.